Press Releases

Press Releases

Date Title  
Dec 09, 2020
Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis
Slowing of neuropathy   progression for all 7 evaluable patients ,   evidenced by   a +1.29 point mean change in NIS ,   was   more favorable than expected progression of +9.2 points Improvement in neuropathy for 3 of these 7 evaluable patients demonstrated by a mean change in NIS of – 3.33 points
Dec 04, 2020
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Dec. 04, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced that
Nov 04, 2020
Prothena Reports Third Quarter 2020 Financial Results and Provides R&D Update
Net cash used in operating and investing activities was $19.5 million   in the third quarter and $61.4 million for the first nine months of 2020; quarter-end cash and restricted cash position of $317.2 million provides funding to advance the R&D pipeline Roche presented results from the Phase 2
Nov 04, 2020
Prothena Announces Presentations on Two Programs from its Alzheimer’s Disease Portfolio at CTAD 2020
Next generation anti- Aβ   antibod ies being developed for subcutaneous administration to improve access for patient s   with Alzheimer’s disease Multi- i mmunogen Aβ- t au va ccine being developed for the prevention and treatment of Alzheimer’s disease DUBLIN, Ireland , Nov.
Oct 28, 2020
Prothena to Report Third Quarter 2020 Financial Results on November 4
DUBLIN, Ireland , Oct. 28, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, announced today that
Oct 20, 2020
Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson’s Disease
First anti-alpha-synuclein antibody to advance into   confirmatory large study in patients with early P arkinson’s disease ; expected to initiate in 2021 Prothena to earn a $60 million   clinical milestone   upon first patient dosed DUBLIN, Ireland , Oct.
Oct 02, 2020
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Oct. 02, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced that in
Sep 15, 2020
Prothena to Hold Investor Webcast to Discuss Results from Phase 2 PASADENA Study Presented at the International Parkinson and Movement Disorder Society's MDS Virtual Congress
DUBLIN, Ireland , Sept. 15, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases will hold an investor
Sep 11, 2020
Prasinezumab Slows Progression on Measures of Parkinson’s Disease in Phase 2 Study
First potentially disease-modifying, anti-alpha-synuclein antibody to demonstrate signals of efficacy on multiple pre-specified secondary and exploratory clinical endpoints, including measures of motor function and biomarkers, in patients with early Parkinson’s disease Significantly reduced decline
Sep 08, 2020
Prothena to Present at the 2020 Cantor Virtual Global Healthcare Conference on September 15
DUBLIN, Ireland , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced that